Reactivation of resolved infection with the hepatitis B virus immune escape mutant G145R during dasatinib treatment for chronic myeloid leukemia

Spontaneous reactivation of hepatitis B virus (HBV) infection in patients with resolved or occult HBV infection

(2015) Hiroshi Kamitsukasa et al.   JOURNAL OF MEDICAL VIROLOGY

ABL kinase mutation and relapse in 4 pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia cases

(2014) Michinori Aoe et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Frequent incidence of escape mutants after successful hepatitis B vaccine response and stopping of nucleos(t)ide analogues in liver transplant recipients

(2014) Masatoshi Ishigami et al.   LIVER TRANSPLANTATION

Ever-advancing chronic myeloid leukemia treatment

(2013) Shinya Kimura et al.   International Journal of Clinical Oncology

Efficacy and safety of dasatinib versus imatinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP): Subset analysis of the DASISION trial with 2-year follow-up

(2013) Shin Fujisawa et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Management of patients with hepatitis B who require immunosuppressive therapy

(2013) Jessica P. Hwang et al.   Nature Reviews Gastroenterology & Hepatology

Hepatitis B reactivation in chronic myeloid leukemia patients receiving tyrosine kinase inhibitor

(2013) Guan-Min Lai   WORLD JOURNAL OF GASTROENTEROLOGY

Dasatinib medication causing profound immunosuppression in a patient after haploidentical SCT: functional assays from whole blood as diagnostic clues

(2012) M Wölfl et al.   BONE MARROW TRANSPLANTATION

Prevention of hepatitis B virus reactivation in patients receiving immunosuppressive therapy or chemotherapy

(2012) Makoto Oketani et al.   HEPATOLOGY RESEARCH

Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy

(2012) S Mustjoki et al.   LEUKEMIA

Reactivation of overt and occult hepatitis B infection in various immunosuppressive settings

(2011) Nicola Coppola et al.   JOURNAL OF MEDICAL VIROLOGY

Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation

(2011) A Kreutzman et al.   LEUKEMIA

Molecular genesis of drug-resistant and vaccine-escape HBV mutants

(2010) Stephen A Locarnini et al.   ANTIVIRAL THERAPY

Nilotinib hampers the proliferation and function of CD8+ T lymphocytes through inhibition of T cell receptor signalling

(2010) J. Chen et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Retrospective and prospective studies of hepatitis B virus reactivation in malignant lymphoma with occult HBV carrier

(2009) N. Fukushima et al.   ANNALS OF ONCOLOGY

Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily

(2009) C. Sillaber et al.   EUROPEAN JOURNAL OF CLINICAL INVESTIGATION

Chronic myeloid leukemia patient manifesting fatal hepatitis B virus reactivation during treatment with imatinib rescued by liver transplantation: case report and literature review

(2009) Byung Woog Kang et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Mortality Secondary to Fulminant Hepatic Failure in Patients with Prior Resolution of Hepatitis B Virus Infection in Japan

(2008) Takeji Umemura et al.   CLINICAL INFECTIOUS DISEASES

Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia

(2008) D. H. Kim et al.   HAEMATOLOGICA

Hepatitis B virus escape mutants induced by antiviral therapy

(2008) J. Sheldon et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Hepatitis B Virus Reactivation in Lymphoma Patients With Prior Resolved Hepatitis B Undergoing Anticancer Therapy With or Without Rituximab

(2008) Winnie Yeo et al.   JOURNAL OF CLINICAL ONCOLOGY